FindTrial
Sign In

SARS-CoV-2 presence in the cerebrospinal fluid of COVID-19 patients with acute respiratory failure: a pilot study.

SARS-CoV-2 presence in the cerebrospinal fluid of COVID-19 patients with acute respiratory failure: a pilot study. - Neuroinvasion in COVID-19

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON49509
Enrollment
10
Registered
2020-04-30
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronavirus COVID-19

Interventions

None listed

Sponsors

Zuyderland Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - At least 18 years of age - Requires mechanical ventilation - Proven SARS-CoV-2 infection - Lumbar puncture possible within 48 hours of ICU admission - Informed consent provided by either patient or legal representative

Exclusion criteria

Exclusion criteria: - Any contraindication for lumbar puncture - Proven or suspected cerebrospinal fluid leak or other blood-brain barrier defects - Any condition known to alter cerebrospinal fluid biochemistry - Known or suspected cause for respiratory failure, other than COVID-19 - Any disease known for decreasing pulmonary capacity or compliance

Design outcomes

Primary

MeasureTime frame
SARS-CoV-2 RT-PCR of cerebrospinal fluid (positive/negative)—

Secondary

MeasureTime frame
Clinical characteristics - 8-week mortality Biochemistry and cell count of the cerebrospinal fluid - Leukocyte count of the cerebrospinal fluid, including differential count Biochemistry and cell count of serum - Leukocyte count - C-reactive protein (CRP) - Lactate dehydrogenase (LDH) - D-Dimer—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)